OVERCOMING CHALLENGES AND OPTIMIZING PROPERTIES

Protein Therapeutics: Triumphs and Challenges
Lynne Regan, Ph.D., Professor, Molecular Biophysics & Biochemistry, Yale University 

Biopolymer ELP-Fusion Protein Technology Significantly Enhances the Pharmacology, Safety, and Efficacy of Biotherapeutics
Adam C. Bell, Ph.D., VP, Development, PhaseBio Pharmaceuticals, Inc.

Optimization and Generation of Fusion Proteins for Therapeutic and Diagnostic Applications
Christopher J. Scott, Ph.D., Director of Research, Molecular Therapeutics, School of Pharmacy, Queens University, Belfast

ENGINEERING THE Fc REGIONS

Fc Fusion Peptide and Protein Biopharmaceuticals – Successes and Challenges
Chichi Huang, Ph.D., Research Fellow, Discovery Research, Centocor R&D, Inc.

Engineering and Characterization of LY2189265, a Novel Long-Acting Glucagon-Like Peptide-1 (GLP-1)-Fc Fusion Protein
Wolfgang Glaesner, Ph.D., CSO-AME, Biotechnology Discovery Research, Lilly Biotechnology Center, San Diego

Engineering Antibody-Cytokine Fusion Proteins (Immunocytokines) for Optimal Anti-Tumor Activity and Reduced Immunogenicity in Patients
Stephen Gillies, Ph.D., Founder, President & CEO, Provenance Biopharmaceuticals Corp.

SEEDbody Fusion Proteins
Alec W. Gross, Ph.D., Principal Investigator, Protein Engineering and Antibody Technologies, EMD Serono Research Institute, Inc.

ENGINEERING INHIBITORS

Targeting Extended Protein Interactions Surfaces with Photo-Switchable Peptides
Katja Arndt, Ph.D., Professor, Molecular Biotechnology, Institute for Biochemistry and Biology, University of Potsdam

Engineering Recombinant Targeted Secretion Inhibitors from Botulinum Neurotoxin
John Chaddock, Ph.D., Head, Portfolio Management and Strategy Implementation, R&D, Syntaxin